Published in Annu Rev Immunol on January 01, 2001
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J (2004) 3.01
Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med (2002) 2.98
Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A (2005) 2.73
Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep (2007) 2.55
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 2.37
Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest (2004) 2.16
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
A genomic approach to human autoimmune diseases. Annu Rev Immunol (2010) 2.10
Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders. Arthritis Rheumatol (2015) 2.08
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol (2009) 2.06
Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev (2008) 1.96
Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med (2011) 1.78
Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) (2010) 1.76
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis (2009) 1.70
Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J Immunol (2008) 1.68
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest (2005) 1.64
TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest (2004) 1.63
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis (2006) 1.62
Angiogenesis in rheumatoid arthritis. Arthritis Res (2002) 1.58
TNF ligands and receptors--a matter of life and death. Br J Pharmacol (2002) 1.57
Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med (2005) 1.55
IκBζ is a key driver in the development of psoriasis. Proc Natl Acad Sci U S A (2015) 1.50
Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann Rheum Dis (2014) 1.48
Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med (2004) 1.48
The story of CD4+ CD28- T cells revisited: solved or still ongoing? J Immunol Res (2015) 1.47
The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol (2007) 1.47
Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. PLoS Pathog (2016) 1.44
Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.43
Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest (2001) 1.40
The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease. Nat Immunol (2016) 1.39
Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther (2009) 1.38
Many cytokines are very useful therapeutic targets in disease. J Clin Invest (2008) 1.33
Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med (2008) 1.30
Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther (2007) 1.29
Joint pain. Exp Brain Res (2009) 1.29
TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci U S A (2006) 1.27
Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol (2009) 1.27
Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther (2010) 1.26
Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol (2006) 1.25
Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition (2008) 1.25
Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J Immunol (2007) 1.22
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine (2014) 1.21
Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin Ther Targets (2003) 1.21
Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. Proc Jpn Acad Ser B Phys Biol Sci (2010) 1.21
Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase. Cell Res (2010) 1.20
Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis (2004) 1.16
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest (2006) 1.15
Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology (2008) 1.15
How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev (2008) 1.15
Sleep loss exacerbates fatigue, depression, and pain in rheumatoid arthritis. Sleep (2012) 1.13
Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis. Inflammation (2011) 1.13
Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther (2006) 1.12
Medical applications of leukocyte surface molecules--the CD molecules. Mol Med (2007) 1.12
Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.11
Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol (2006) 1.11
Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum (2009) 1.11
Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther (2009) 1.10
Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res (2002) 1.10
Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. [corrected]. Life Sci (2010) 1.09
Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther (2004) 1.07
Investigation into the anti-inflammatory and antigranuloma activity of Colchicum luteum Baker in experimental models. Inflammation (2012) 1.07
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol (2008) 1.07
FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS One (2012) 1.07
Tendons--time to revisit inflammation. Br J Sports Med (2013) 1.05
The death domain kinase RIP1 is essential for tumor necrosis factor alpha signaling to p38 mitogen-activated protein kinase. Mol Cell Biol (2003) 1.05
Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs. Chem Biol (2010) 1.05
Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol Lett (2008) 1.04
Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus. Rheumatol Int (2010) 1.03
Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis (2005) 1.03
Cytokines in systemic lupus erythematosus. Curr Mol Med (2009) 1.03
Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol (2007) 1.02
Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int (2007) 1.02
The co-expression of activating and inhibitory leukocyte immunoglobulin-like receptors in rheumatoid synovium. Am J Pathol (2002) 1.02
Cytokine regulation in RA synovial tissue: role of T cell/macrophage contact-dependent interactions. Arthritis Res (2002) 1.01
TNF and receptors in organ-specific autoimmune disease: multi-layered functioning mirrored in animal models. J Clin Invest (2001) 1.01
Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther (2009) 1.01
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes (2013) 1.01
The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. Rheumatol Int (2004) 0.99
Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets (2014) 0.99
Experimental human endotoxemia: a model of the systemic inflammatory response syndrome? Surg Infect (Larchmt) (2012) 0.98
Selective expansion of CD16highCCR2- subpopulation of circulating monocytes with preferential production of haem oxygenase (HO)-1 in response to acute inflammation. Clin Exp Immunol (2005) 0.98
Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res (2002) 0.98
Tocilizumab. MAbs (2009) 0.97
Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. Ann Rheum Dis (2007) 0.97
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol (2002) 0.97
How are the regulators regulated? The search for mechanisms that impose specificity on induction of cell death and NF-kappaB activation by members of the TNF/NGF receptor family. Arthritis Res (2002) 0.96
Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis. Arthritis Res Ther (2008) 0.96
Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol (2013) 0.95
Cell therapy for autoimmune diseases. Arthritis Res Ther (2007) 0.95
Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection. J Virol (2004) 0.95
Transient decrease in nociceptor GRK2 expression produces long-term enhancement in inflammatory pain. Neuroscience (2012) 0.95
The future of osteoarthritis therapeutics: emerging biological therapy. Curr Rheumatol Rep (2013) 0.95
Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol (2014) 0.94
The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.94
CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proc Natl Acad Sci U S A (2013) 0.93
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 10.22
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Rheumatoid arthritis. Cell (1996) 6.01
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
A micro-method for peripheral leucocyte migration in tuberculin sensitivity. J Clin Pathol (1971) 3.45
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res (2000) 2.37
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Measurement of DNA antibodies by double antibody precipitation. Ann Rheum Dis (1973) 2.21
The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. Q J Med (1979) 2.07
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
The clinical significance of mediators of cellular immunity. Clin Allergy (1971) 2.03
Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Br Med J (1978) 2.01
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum (1985) 1.99
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum (1998) 1.79
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
Purification and characterization of the Sjögren's syndrome A and B antigens. Clin Exp Immunol (1983) 1.73
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis (1975) 1.67
HLA and rheumatoid arthritis: a combined analysis of 440 British patients. Ann Rheum Dis (1986) 1.66
Evidence of Chlamydia trachomatis infection in sexually acquired reactive arthritis. Ann Rheum Dis (1980) 1.65
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 1.59
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum (2004) 1.56
Murine lupus monoclonal antibodies define five epitopes on two different Sm polypeptides. Immunology (1986) 1.54
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol (1997) 1.53
Serological and immunogenetic markers of extraglandular primary Sjögren's syndrome. Br J Rheumatol (1993) 1.53
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum (1992) 1.53
DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol (1997) 1.52
Lymphocyte mitogenic factor in man. Nature (1969) 1.51
Titers of antibodies to RANA in rheumatoid arthritis and normal sera. Relationship to Epstein-Barr virus infection. Arthritis Rheum (1981) 1.49
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum (2000) 1.49
Quantitation and detection of isotypes of anti-SS-B antibodies by ELISA and Farr assays using affinity purified antigens. An approach to the investigation of Sjögren's syndrome and systemic lupus erythematosus. Arthritis Rheum (1983) 1.48
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1996) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Antibodies to extractable nuclear antigens in rheumatoid arthritis: relationship to vasculitis and circulating immune complexes. Clin Exp Immunol (1980) 1.47
Monoclonal antibodies to the Sjögren's syndrome associated antigen SS-B (La). J Immunol Methods (1985) 1.46
Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol (1997) 1.46
Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol (1992) 1.44
Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A (1994) 1.42
Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis (1984) 1.41
Standardization of the leucocyte migration test. Int Arch Allergy Appl Immunol (1973) 1.39
The association of cryoglobulinaemia with nodules, vasculitis and fibrosing alveolitis in rheumatoid arthritis and their relationship to serum C1q binding activity and rheumatoid factor. Clin Exp Immunol (1979) 1.39
Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis (1990) 1.38
Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum (2002) 1.38
Virus infection induces redistribution and membrane localization of the nuclear antigen La (SS-B): a possible mechanism for autoimmunity. Clin Exp Immunol (1989) 1.36
Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol (1999) 1.35
Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun (1989) 1.33
T cells expressing gamma delta chain receptors in rheumatoid arthritis. J Autoimmun (1988) 1.32
Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis (1989) 1.31
The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.29
The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol (1992) 1.27
Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol (2000) 1.27
Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol (1998) 1.27
The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun (2001) 1.26
Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol (1997) 1.26
High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum (1995) 1.26
Coordinate expansion of 'fetal type' lymphocytes (TCR gamma delta+T and CD5+B) in rheumatoid arthritis and primary Sjögren's syndrome. Clin Exp Immunol (1989) 1.25
Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol (1997) 1.23
Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. J Immunol Methods (1982) 1.23
Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis (1988) 1.23
Separation of two molecular species of the Sm antigen by affinity chromatography with murine monoclonal and human anti-nuclear autoantibodies. Clin Exp Immunol (1983) 1.22
HLA antigen associations with extra-articular rheumatoid arthritis. Tissue Antigens (1984) 1.22
Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum (1993) 1.22
Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum (2000) 1.22
The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods (1991) 1.19
Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol (1997) 1.19
Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. J Autoimmun (1990) 1.17
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol (1997) 1.16
The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease. Clin Exp Immunol (1982) 1.15
Cytokine expression in rheumatoid arthritis. Br J Rheumatol (1991) 1.14
Antibodies to La, Jo-1, nRNP and Sm detected by multi-track immunoblotting using a novel filter holder: a comparative study with counterimmunoelectrophoresis and immunodiffusion using sera from patients with systemic lupus erythematosus and Sjögren's syndrome. J Immunol Methods (1986) 1.14
Antibodies to the mycobacterial 65-kd heat-shock protein are reactive with synovial tissue of adjuvant arthritic rats and patients with rheumatoid arthritis and osteoarthritis. Am J Pathol (1990) 1.14
Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol (1992) 1.13
Bradycardiac angina. Am Heart J (1970) 1.13
Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Clin Exp Immunol (1992) 1.13
Anti-cardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes. Clin Exp Immunol (1989) 1.12
Peripheral leucocyte migration. Inhibited by diphtheroid organisms isolated from patients with rheumatoid arthritis. Ann Rheum Dis (1970) 1.10
Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population. Clin Exp Immunol (1993) 1.10
The production of lymphocyte mitogenic factor and migration-inhibition factor by antigen-stimulated lymphocytes of subjects with grass pollen allergy. Clin Exp Immunol (1971) 1.09
IgE and IgE-rheumatoid factors in circulating immune complexes in rheumatoid arthritis. Ann Rheum Dis (1982) 1.09